InnoCare Advances Phase III AML Trial of Mesutoclax

BEIJING, August 18, 2026

Phase III Trial Targets Treatment-Naive AML

The newly approved Phase III AML trial will directly compare mesutoclax plus azacitidine with venetoclax plus azacitidine in elderly or unfit patients who have not previously received treatment for AML. The study’s primary endpoint is overall survival (OS), making the trial particularly important for determining whether mesutoclax can provide a meaningful clinical advantage over an established BCL2 inhibitor regimen. The randomized, multicenter design is intended to generate robust comparative evidence as InnoCare progresses the candidate toward potential registration. AML is an aggressive hematologic malignancy that originates from abnormal hematopoietic stem or progenitor cells, with incidence increasing significantly with age. For older patients and those unable to tolerate intensive chemotherapy, effective lower-intensity treatment options remain an important area of unmet medical need.

Mesutoclax Shows Promising Clinical Activity

Mesutoclax is designed to selectively inhibit BCL2, an important regulatory protein involved in the apoptosis pathway. By inhibiting BCL2, mesutoclax is intended to restore programmed cell death in cancer cells and produce antitumor activity. The candidate has received two Breakthrough Therapy Designations from China’s CDE, highlighting its potential importance in AML development. Data presented at the 2026 ASCO Annual Meeting showed encouraging activity for mesutoclax in combination with azacitidine among treatment-naive AML patients. As of April 13, 2026, 81.8% of evaluable patients achieved composite complete remission (cCR), defined as complete remission or complete remission with incomplete hematologic recovery. Among patients achieving an overall response, 86.5% were minimal residual disease (MRD) negative, while 83% of cCR responders achieved remission during the first treatment cycle. These findings indicate rapid and deep responses in the evaluated population. The reported safety profile was also encouraging, with no dose-limiting toxicities observed, the maximum tolerated dose not reached, and zero reported 30-day and 60-day mortality among treatment-naive AML patients in the presented dataset. At the recommended dose, the reported six-month overall survival rate was 90.5%.

Global Clinical Development Expands

The approval of the registrational Phase III study represents another step in InnoCare’s strategy to advance mesutoclax as a global AML therapy. The company is already accelerating international development of mesutoclax in combination with azacitidine, with patients enrolled in clinical studies in the United States and Australia. The new head-to-head Phase III study will provide an opportunity to evaluate the candidate directly against venetoclax, an established BCL2-targeting therapy used in combination with azacitidine for patients with AML who are unable to undergo intensive chemotherapy. If the study demonstrates superiority on overall survival and meets other required endpoints, the findings could support future regulatory submissions and broaden treatment options for older and medically unfit AML patients. InnoCare is a commercial-stage biopharmaceutical company focused on innovative therapies for cancer and autoimmune diseases, with multiple approved products and a broad clinical and preclinical pipeline. The advancement of mesutoclax into a registrational Phase III program underscores the company’s continued investment in hematologic cancer drug development and precision-targeted therapies.

Source: InnoCare Pharma press relese